C
58.80
2.69 (4.79%)
| 前收盘价格 | 56.11 |
| 收盘价格 | 55.79 |
| 成交量 | 993,851 |
| 平均成交量 (3个月) | 1,053,539 |
| 市值 | 4,858,308,096 |
| 价格/销量 (P/S) | 5.22 |
| 股市价格/股市净资产 (P/B) | 4.53 |
| 52周波幅 | |
| 利润日期 | 12 May 2026 |
| 营业利益率 (TTM) | -81,161.54% |
| 稀释每股收益 (EPS TTM) | -1.50 |
| 季度收入增长率 (YOY) | -90.20% |
| 总债务/股东权益 (D/E MRQ) | 0.15% |
| 流动比率 (MRQ) | 30.97 |
| 营业现金流 (OCF TTM) | -81.98 M |
| 杠杆自由现金流 (LFCF TTM) | -57.18 M |
| 资产报酬率 (ROA TTM) | -12.85% |
| 股东权益报酬率 (ROE TTM) | -16.58% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | CG Oncology, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
1.0
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.00 |
|
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 1.17% |
| 机构持股比例 | 105.34% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Foresite Capital Management Vi Llc | 31 Dec 2025 | 2,221,474 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 80.00 (HC Wainwright & Co., 36.05%) | 购买 |
| 中 | 73.00 (24.15%) | |
| 低 | 70.00 (Piper Sandler, 19.05%) | 购买 |
| 70.00 (Wedbush, 19.05%) | 购买 | |
| 平均值 | 73.60 (25.17%) | |
| 总计 | 5 购买 | |
| 平均价格@调整类型 | 53.07 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 27 Feb 2026 | 80.00 (36.05%) | 购买 | 58.80 |
| Truist Securities | 10 Feb 2026 | 75.00 (27.55%) | 购买 | 53.09 |
| 12 Jan 2026 | 66.00 (12.24%) | 购买 | 53.72 | |
| RBC Capital | 21 Jan 2026 | 73.00 (24.15%) | 购买 | 57.13 |
| Piper Sandler | 16 Jan 2026 | 70.00 (19.05%) | 购买 | 54.73 |
| Wedbush | 11 Dec 2025 | 70.00 (19.05%) | 购买 | 41.61 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合